middle.news
How Neurizon’s NUZ-001 Is Poised to Transform ALS Treatment After FDA Clearance
10:36am on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
How Neurizon’s NUZ-001 Is Poised to Transform ALS Treatment After FDA Clearance
10:36am on Wednesday 25th of February, 2026 AEDT
Key Points
Half-year loss narrowed to $5.54 million from $7.28 million
Exclusive global license secured with Elanco for NUZ-001
FDA lifts clinical hold, clearing IND application for ALS treatment
Positive Phase 1 Open-Label Extension study results support safety and efficacy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEURIZON THERAPEUTICS (ASX:NUZ)
OPEN ARTICLE